Phase 1/2 × Congenital Abnormalities × Cytarabine × Clear all Sorafenib and Low Dose Cytarabine in Older Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Phase 1/2 Completed
21 enrolled
Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia
Phase 1/2 Terminated
20 enrolled 9 charts
Clofarabine, Cytarabine, and G-CSF in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1/2 Completed
50 enrolled 13 charts
Clofarabine and Cytarabine in Treating Older Patients With AML or High-Risk MDS
Phase 1/2 Completed
35 enrolled 11 charts
Lestaurtinib, Cytarabine, and Idarubicin in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1/2 Completed
14 enrolled 9 charts
Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Myeloid Cancer
Phase 1/2 Completed
32 enrolled 9 charts
Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
Phase 1/2 Completed
95 enrolled 9 charts
Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia
Phase 1/2 Completed
95 enrolled 5 charts
A Phase I/II Study of Induction Chemotherapy With Daunorubicin, Cytarabine, Topotecan and Etoposide
Phase 1/2 Completed
41 enrolled
AML-14A
Phase 1/2 Unknown
114 enrolled
Laromustine, Daunorubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia
Phase 1/2 Completed
135 enrolled
Chemotherapy Followed by Donor White Blood Cells Plus Interleukin-2 in Treating Patients With Acute Myeloid or Lymphocytic Leukemia
Phase 1/2 Completed